Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,545 questions · 2,661 findings · 317 reviews

No studies found 608 · 22.8%GRADE not reported 505 · 19%Very low 695 · 26.1%Low 540 · 20.3%Moderate 249 · 9.4%High 64 · 2.4%

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with cognitive behavioural therapy + placebo (very low certainty).

1 finding from 1 review

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis

It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: specific ‐ doctors' assessment of adverse effects… compared with cognitive behavioural therapy + placebo (very low certainty).

1 finding from 1 review

Group B cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo and cognitive and behavioural therapies

Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with cognitive behavioural therapy + placebo (very low certainty).

1 finding from 1 review

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with supportive therapy + placebo (very low certainty).

1 finding from 1 review

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis

It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: doctors' assessment of adverse effects UKU (events)… compared with supportive therapy + placebo (very low certainty).

1 finding from 1 review

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with supportive therapy + placebo (very low certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Dropouts ‐ Any dose · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3 weeks for 27 weeks) vs placebo injection

Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3… showed no clear difference in mean number of oral ulcers compared with placebo (saline IM injection); GRADE not reported.

1 finding from 1 review